Changeflow GovPing

What do you monitor?

Curated feeds for your role. Pick your area and get exactly the sources you need.

Recent changes

Favicon for www.courtlistener.com

People v. Pollard - Felony Reckless Evation Appeal

The California Court of Appeal filed an opinion in the case of People v. Pollard, concerning a felony reckless evasion charge. The court is reviewing whether the trial court erred in instructing the jury on the underlying traffic violations for the evasion charge.

Routine Enforcement Criminal Justice
27d ago Ofcom News Centre
Favicon for www.ofcom.org.uk

Ofcom provisionally finds suicide forum in breach of Online Safety Act

Ofcom has provisionally found a provider of an online suicide forum in breach of the UK's Online Safety Act. The provider failed to conduct adequate risk assessments and implement proportionate measures to protect users from illegal content. Ofcom is considering sanctions, including potential fines or business disruption measures.

Urgent Enforcement Data Privacy
Favicon for www.cand.uscourts.gov

Medina Jimenez v. Tesla, Inc. - Notice of Removal

Tesla, Inc. has filed a Notice of Removal in the case Medina Jimenez v. Tesla, Inc., case number 3:26-cv-01727, in the U.S. District Court for the Northern District of California. The case was originally filed in Alameda Superior Court and has been removed to federal court.

Routine Enforcement Judicial Administration
Favicon for rules.house.gov

H.R. 4638 - BOWOW Act of 2025 Hearing Announcement

The US House Committee on the Judiciary announced a hearing for H.R. 4638, the BOWOW Act of 2025, scheduled for March 3, 2026. The bill text and committee report are available for review.

Routine Notice Government Contracting
Favicon for rules.house.gov

H.R. 4638 BOWOW Act of 2025 - Immigration inadmissibility for harming law enforcement animals

H.R. 4638, the BOWOW Act of 2025, was introduced in the US House of Representatives. This bill proposes to amend the Immigration and Nationality Act to make aliens inadmissible and deportable if convicted of harming animals used in law enforcement.

Priority review Rule Immigration
Favicon for rules.house.gov

H.R. 1958 Deporting Fraudsters Act Hearing Announcement

The US House Committee on the Judiciary announced a hearing for H.R. 1958, the Deporting Fraudsters Act of 2026. The hearing is scheduled for Tuesday, March 3, 2026, and will discuss the proposed legislation.

Routine Notice Immigration
Favicon for rules.house.gov

HR 1958: Deporting Fraudsters Act of 2026

The "Deporting Fraudsters Act of 2026" (H.R. 1958) amends the Immigration and Nationality Act to make aliens convicted of defrauding the U.S. government or unlawfully receiving public benefits inadmissible and deportable. This bill was reported by the House Committee on the Judiciary and ordered to be printed.

Priority review Rule Immigration
Favicon for www.tdi.texas.gov

NCCI Loss Costs Accepted with 3.8% Decrease for Workers' Compensation

The Texas Department of Insurance (TDI) has accepted the NCCI advisory loss cost filing, resulting in an average 3.8% decrease for workers' compensation insurance, effective July 1, 2026. Insurance companies writing workers' compensation in Texas must submit rate filings by June 1, 2026, using the new loss costs.

Priority review Guidance Insurance
27d ago EMA News
Favicon for www.ema.europa.eu

EMA CHMP Recommends 12 Medicines for Approval

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended 12 new medicines for approval and six for extension of therapeutic indications. This includes novel treatments for influenza, COVID-19, paediatric brain tumours, Parkinson's disease, and several biosimilar medicines.

Priority review Notice Pharmaceuticals
27d ago EMA News
Favicon for www.ema.europa.eu

EMA Recommends Ojemda for Paediatric Low-Grade Glioma

The European Medicines Agency (EMA) has recommended a conditional marketing authorisation for Ojemda (tovorafenib) to treat paediatric low-grade glioma in patients aged 6 months and older with specific BRAF gene alterations. This recommendation addresses an unmet medical need for a targeted therapy in this patient population.

Priority review Guidance Pharmaceuticals

Showing 26111–26120 of 28,220 changes

1 2610 2611 2612 2613 2614 2822

Get alerts when regulations change

Weekly digest. AI-summarized, no noise.

Free. Unsubscribe anytime.